Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01712490 · FLOW

Participant flow

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma · Source last updated 2026-02-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.
    id
    FG000
    title
    A+AVD
  2. description
    Doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.
    id
    FG001
    title
    ABVD
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        601
      2. group Id
        FG001
        num Subjects
        586
      type
      Ongoing
    2. reasons
      1. group Id
        FG000
        num Subjects
        11
      2. group Id
        FG001
        num Subjects
        11
      type
      Other
    3. reasons
      1. group Id
        FG000
        num Subjects
        36
      2. group Id
        FG001
        num Subjects
        44
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        16
      2. group Id
        FG001
        num Subjects
        29
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        664
      2. group Id
        FG001
        num Subjects
        670
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        662
      2. group Id
        FG001
        num Subjects
        659
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        664
      2. group Id
        FG001
        num Subjects
        670
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants with histologically confirmed diagnosis of advanced classical hodgkin lymphoma (cHL) were enrolled to receive: brentuximab vedotin 1.2 mg/kg plus doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (A+AVD) or doxorubicin 25 mg/m\^2, bleomycin 10 units/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (ABVD).
recruitment Details
Participants took part in the study at 218 investigative sites in Asia Pacific, Europe, Latin America, and North America from 09 November 2012 to the primary completion date of 20 April 2017.
Complete source fields
groups
  1. description
    Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.
    id
    FG000
    title
    A+AVD
  2. description
    Doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.
    id
    FG001
    title
    ABVD
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        601
      2. group Id
        FG001
        num Subjects
        586
      type
      Ongoing
    2. reasons
      1. group Id
        FG000
        num Subjects
        11
      2. group Id
        FG001
        num Subjects
        11
      type
      Other
    3. reasons
      1. group Id
        FG000
        num Subjects
        36
      2. group Id
        FG001
        num Subjects
        44
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        16
      2. group Id
        FG001
        num Subjects
        29
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        664
      2. group Id
        FG001
        num Subjects
        670
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        662
      2. group Id
        FG001
        num Subjects
        659
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        664
      2. group Id
        FG001
        num Subjects
        670
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants with histologically confirmed diagnosis of advanced classical hodgkin lymphoma (cHL) were enrolled to receive: brentuximab vedotin 1.2 mg/kg plus doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (A+AVD) or doxorubicin 25 mg/m\^2, bleomycin 10 units/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (ABVD).
recruitment Details
Participants took part in the study at 218 investigative sites in Asia Pacific, Europe, Latin America, and North America from 09 November 2012 to the primary completion date of 20 April 2017.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice